Biomarkers
Research type
Research Study
Full title
Biomarker validation
IRAS ID
264725
Contact name
Sharmilee Gnanapavan
Contact email
Sponsor organisation
Barts Health NHS Trust
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
This is a project to set up novel biomarkers of prognostic significance in multiple sclerosis.
The main project is a cross-sectional and longitudinal biomarker study to evaluate the accuracy of serum neurofilament measurements in substituting for cerebrospinal fluid neurofilament measurements, and whether it is predictive of clinical and MRI changes. The cerebrospinal fluid neurofilaments is the only test currently available for clinical use, and is performed by the Department of Neuroscience & Trauma, Blizard Institute.
In addition we will be establishing age-related serum cut-offs using healthy controls as neurofilament measurements are know to rise with ageing, as part of normal neuronal turnover.
In the future, we plan to explore other novel biomarkers in MS in this sample set.
REC name
London - City & East Research Ethics Committee
REC reference
20/LO/0023
Date of REC Opinion
20 Jan 2020
REC opinion
Favourable Opinion